



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Dated: 31 Aug, 2021

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India
Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited has received DCG(i) approval for '2-Deoxy-2-Glucose' (Bulk & Oral Powder)

This is to inform you that the Company has received DCG(i) approval for 2-Deoxy-2-Glucose (Bulk & Oral Powder). The bulk is manufactured by Shilpa Medicare Limited, API facility in Raichur, Karnataka. The Oral Powder is manufactured by its subsidiary, Shilpa Therapeutics, facility in Hyderabad, Telangana.

2-Deoxy-2-Glucose Oral Powder is approved for the treatment of adjunct therapy in moderate to severe COVID-19 patients. The product will be available with a brand name '2-DGSHIL'.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**




V V Krishna Chaitanya
Company Secretary &
Compliance Officer.